MIM
LUMO

MetLife Investment Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

MetLife Investment Management’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,250
Closed -$91K – 2219
2017
Q4 		$91K Buy
+1,250
New +$103K ﹤0.01% 2200

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MetLife Investment Management's LUMO Position: Q1 2018 in Review

MetLife Investment Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2018, closing a stake of 1,250 shares — an estimated $91K sold.

MetLife Investment Management first reported a position in LUMO in Q4 2017 and held it in 1 quarter. The position peaked at $91K in Q4 2017. 126 funds tracked by Wall St. Rank hold LUMO as of Q1 2018.

  • MetLife Investment Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • MetLife Investment Management sold 1,250 Lumos Pharma, Inc. Common Stock shares in Q1 2018, an estimated $91K.
  • MetLife Investment Management first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • MetLife Investment Management's Lumos Pharma, Inc. Common Stock position peaked at $91K in Q4 2017.
  • 126 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2018.

Based on MetLife Investment Management's 13F filing for Q1 2018, filed 15 May 2018.